The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.
The discovery of CCR5 as a HIV-1 co-receptor unfolded the cryptic and complicated process of HIV-1 cellular entry and has provided more than a few entry steps as possible modalities for effective viral intervention. The proof-of-principle has already been established for the use of entry inhibitors against HIV-1 and there is a cautious optimism that several CCR5 inhibitors might soon be added to our armamentarium for therapy of HIV-1 infection.
Maeda
Kenji
K
Department of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto 860-8556, Japan.
Nakata
Hirotomo
H
Ogata
Hiromi
H
Koh
Yasuhiro
Y
Miyakawa
Toshikazu
T
Mitsuya
Hiroaki
H
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists